Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring

Table 1 Classification of reporting countries into priority groups

Malaria control phase[1]/Income[21]	Low income	Middle income	High income
Control	Priority 1	Priority 2	Priority 3
Pre-elimination/elimination	Priority 2	Priority 2	Priority 3
Prevention of reintroduction/Malaria free	Priority 3	Priority 3	Priority 3

ISSN: 1475-2875